DNDi welcomes Astellas to the NTD Drug Discovery Booster

The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.

Toremaga [8 December, 2016]

スーダン・ハルツーム大学のアーメド ファハル外科教授が来日 重篤な感染症「マイセトーマ(菌腫)」について講演を行う” – “Professor Ahmed Fahal, surgeon from Sudan / Khartoum University will give a lecture on the serious infectious disease: Mycetoma”

Click here to read the article

Renewed commitment of the German Government to neglected diseases

KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi

DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.